Tag: IO
Unifying IO globally: IASIOS reports first US accredited centre
The International Accreditation System for Interventional Oncology Services (IASIOS) is the world’s first accreditation programme focused exclusively on standardising interventional oncology (IO) care, redefining...
Alda Tam
Alda Tam is an interventional radiologist and professor at the University of Texas MD Anderson Cancer Center in Houston, USA, and is current president...
IASIOS reports first accredited centre in the USA
The International Accreditation System for Interventional Oncology Services (IASIOS) has reported experiencing exponential growth exceeding 150% in the past year. IASIOS has been at...
#HOPE4LIVER trial demonstrates safety and efficacy of histotripsy for liver tumours
The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2023 annual meeting (9–13 September, Copenhagen, Denmark) played host to another FIRST@CIRSE session, which saw...
Micromate: Your robotic assistant for all needle interventions from head to...
This advertorial is sponsored by Interventional Systems.
Achieving consistency, accuracy, and ease of use in interventional radiology (IR) and interventional oncology (IO) procedures, including biopsy...
Fifty patients treated with Epione robot at the Hospices Civils de...
The 50th patient has been treated using the Epione robot from Quantum Surgical by the team of Laurent Milot, deputy chief vascular and interventional...
First patient treated with Epione robot in USA
Govindarajan Narayanan, chief of interventional oncology at Miami Cancer Institute and a vascular interventional radiologist with Miami Cardiac & Vascular Institute (both Miami, USA),...
Speakers shine light on current evidence for the ‘IOs’ and the...
Two of the sessions from day one of the 2023 European Conference on Interventional Oncology (ECIO; 16–19 April, Stockholm, Sweden) drew delegates’ focus to...
Cryoablation for renal cell carcinoma: Where do we stand? Where are...
Christos Georgiades (Johns Hopkins University, Baltimore, USA), delves into the various national society guidelines for treating renal cell carcinoma (RCC), what the ‘gold standard’...
IO beyond interventional oncology: Progress in immuno-oncology
Recent advances in immuno-oncology are transforming the practice of medical oncology. Currently, antibodies directed against negative regulators of T-cell function, the so-called checkpoint inhibitors,...
Delcath Systems announces US FDA acceptance of Hepzato Kit new drug...
Delcath Systems has announced in a company press release that the US Food and Drug Administration (FDA) has accepted its (Delcath's) new drug application...
SurgVision’s Explorer Air II granted US FDA 510(k) clearance
SurgVision, a company developing pioneering solutions for fluorescence-guided surgical and interventional oncology, part of the Bracco Group, has announced that it has received 510(k)...
Interventional News’ top 10 most popular stories of February 2023
Interventional News’ most popular stories for the month of February included news from the Pan Arab Interventional Radiology Society annual meeting (PAIRS; 11–14 February,...
PAIRS 2023: What the BCLC guidelines have omitted
Sarah White (Medical College of Wisconsin, Milwaukee, USA) opened the liver interventional oncology (IO) session at the Pan Arab Interventional Radiology Society (PAIRS) annual...
Histotripsy: New technology making waves in IO
Mina S Makary, assistant professor at the Division of Vascular and Interventional Radiology/Department of Radiology at the Ohio State University Wexner Medical Center (Columbus,...
Patient-centric care: Recognising the value of non-clinical intervention
During the Society of Interventional Oncology (SIO) 2023 annual scientific meeting in Washington DC, USA, a panel of speakers delivered presentations on why patient-centred...
New consensus guidelines will facilitate interventional oncology research
We are facing several problems in the field of clinical oncology research, by which I mean that study results are being collected, analysed and...
Guidelines will boost interventional oncology research
The development of new research guidelines for interventional oncology that standardise treatment outcomes and the reporting of data represents a major step forward for...
Combination of immuno-oncology and liver-directed therapy: Where do we stand?
Ushering in “the era of IO”, Brad Wood calls for interventional oncologists to learn the language of immuno-oncology—“the other IO”—in order to improve care...
Interventional Oncology 2.0: Soul-searching to define our identity
Julius Chapiro and Lynn Savic claim there is “no need for scepticism” about the recent emergence and growth of immuno-oncology from an interventional oncologists’...
International accreditation scheme “brings IO into the mainstream”
The newly established International Accreditation System for Interventional Oncology Services (IASIOS) gives medical facilities the opportunity to receive credentials for their interventional oncology (IO)...
Interventional oncology established in “mainstream” cancer care with world-first clinical symposium
The world-first collaboration between interventional oncology (IO) and radiation oncology, embraced by the Trans-Tasman Radiation Oncology Group (TROG), continues to bear fruit, with the...
New augmented reality system lets IRs “literally see through the patient”
European Radiology Experimental has recently published a study on a new augmented reality system that is able to accurately guide interventional oncology procedures. A three-step...
WCIO 2018 puts biopsy front and centre of the interventional oncology...
The opening plenary at the World Conference on Interventional Oncology (WCIO; 7–10 June, Boston, USA) put biopsy, which is considered a mundane procedure by...
Artificial intelligence will support clinical decision making in interventional oncology
Aaron Abajian and Julius Chapiro, New Haven, USA, write about results from an early experiment in applying artificial intelligence (AI) and machine learning as a...
Guerbet announces Lausanne partnership to evaluate immunogenic potential of cTACE
Guerbet has announced a partnership with the Department of Radiodiagnosis and Interventional Radiology of Lausanne's University Hospital (CHUV) and the Lausanne Center for Experimental...
Targeted immunotherapy treatment shows promise for treating for advanced liver cancer
Advanced stage liver tumours may be safely treated through image-guided injections of an immunotherapy approved for melanoma, according to phase 1 data presented at...
Mentice aims to reduce TACE procedure times and radiation exposure with...
Mentice has announced the release of a new simulation training software for transarterial chemoembolization (TACE). The new software was showcased at the 2017 CIRSE...
Gore Viatorr TIPS Endoprosthesis with Controlled Expansion may reduce portal hypertension...
The Gore Viatorr TIPS endoprosthesis with Controlled Expansion, a new device configuration developed by Gore, may reduce portal hypertension treatment complications, even when compared...
Stephen Solomon assumes Society of Interventional Oncology presidency
The Society of Interventional Oncology (SIO) has announced new officers and a Board of Directors.
Stephen Solomon, chief of Interventional Radiology at Memorial Sloan Kettering...
WCIO session highlights the pick of recent interventional oncology research
A session at the World Conference on Interventional Oncology (WCIO; 8–11 June, Boston, USA), organised by the Society of Interventional Oncology (SIO), identified the...
Interventional oncology should identify “unmet immunotherapy needs”
Daniel Sze, speaking at the ninth annual Symposium on Clinical Interventional Oncology (CIO; 4–5 February 2017, Hollywood, USA), noted that immunotherapy is a “huge...
SIRT access “under threat” from commissioning through evaluation process
Selective internal radiation therapy (SIRT) has been available since December 2013 to a defined group of patients with liver metastases in England on the...
